GSK terminates collaboration on IDE275 and IDE705; programs returning to IDEAYA

IDEAYA Biosciences, Inc.

GSK gave written notice on Dec 9, 2025 to terminate the June 2020 Collaboration, Option and License Agreement.
Termination effective March 9, 2026; 90-day transition for GSK to transfer Werner Helicase (IDE275) and Pol Theta (IDE705) programs.
IDEAYA will evaluate strategic options for IDE275 and IDE705 in 2026.
Cash runway guidance into 2030 remains unchanged despite the termination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.